Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00889525|
Recruitment Status : Completed
First Posted : April 29, 2009
Last Update Posted : April 29, 2009
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.
Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
|Condition or disease||Intervention/treatment||Phase|
|Cushing's Disease Corticotroph Adenoma||Drug: Cabergoline||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor|
|Study Start Date :||November 2007|
U.S. FDA Resources
Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
- Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00889525
|Seth GSMC & KEM hospital|
|Mumbai, Maharashtra, India, 4000012|
|Principal Investigator:||Nalini S Shah, DM||Seth GSMC and KEM hospital, Mumbai|